ARTHEx Biotech

About:

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.

Website: https://arthexbiotech.com/

Twitter/X: Arthexbiotech

Top Investors: European Innovation Council, Invivo Capital Partners, Centre for the Development of Industrial Technology (CDTI), Columbus Venture Partners, AdBio partners

Description:

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.